FDA Gearing Up To Standardize Clinical Trial Results In Labeling
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA is gearing up to review and standardize the way that clinical trial results are reported in labeling
You may also be interested in...
It's Up To Stakeholders To Further The PRO Measurement Field, FDA Says
FDA is preparing to issue its final guidance on patient-reported outcomes soon, which will codify the agency's approach to validating PROs used as clinical endpoints, but a recent workshop made clear that there is still a substantial amount of work to be done on identifying and creating appropriate measurements of patient-, clinician- and caregiver-reported outcomes
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011